<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364849">
  <stage>Registered</stage>
  <submitdate>31/08/2013</submitdate>
  <approvaldate>4/09/2013</approvaldate>
  <actrnumber>ACTRN12613000985785</actrnumber>
  <trial_identification>
    <studytitle>The NIFTY study: A Multi-centre Randomised Double Blind Placebo Controlled Trial of Nifedipine Maintenance Tocolysis in Fetal Fibronectin Positive Women in Threatened Preterm Labour</studytitle>
    <scientifictitle>Effect of Maintenance Tocolysis with Nifedipine on Prolongation of Pregnancy in Women with Threatened Preterm Labour and Positive Fetal Fibronectin Status</scientifictitle>
    <utrn />
    <trialacronym>NIFTY</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Preterm Labour</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fetal medicine and complications of pregnancy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1: Nifedipine orally slow release 20 mg eight hourly, on occasion this may be increased up to a maximum of 160 mg in 24 hours (in case of ongoing contractions) until 36 completed gestational weeks
Arm 2: Identical placebo</interventions>
    <comparator>Placebo, ironoxide</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Duration of pregnancy, time between randomisation and delivery.</outcome>
      <timepoint>End of pregnancy, defined as date of delivery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Reduction of neonatal admission by greater than 4 days</outcome>
      <timepoint>At discharge from neonatal admission unit, duration of neonatal admission defined by discharge date minus admission date</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women with threatened preterm labour, a singleton pregnancy, gestational age between 24 and 34 weeks, intact membranes, positive fetal fibronectin test, completed course of corticosteroids</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Ruptured membranes, suspicion of chorioamnionitis, antepartum haemorrhage or suspected concealed abruption, major fetal anomaly, contraindication to nifedipine treatment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation involved contacting the holder of the allocation schedule who was at central administration site</concealment>
    <sequence>Randomisation using computer generated numbers</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>In a previous study at National Women's Hospital, it was shown that women in preterm labour who were Fetal Fibronectin positive had a median time from presentation to delivery of 35 days, whereas those who were fibronectin negative had a median time to delivery of 51 days. If nifedipine treatment increased the duration of pregnancy by at least seven days in those who were positive, that would be a substantial benefit to the infant. The sample size required to extend the duration of pregnancy by seven days (SD14) was 50 in each group, with a power of 80% at a significance level of 0.05 (two-sided). </statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/09/2003</anticipatedstartdate>
    <actualstartdate>18/10/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate>25/07/2007</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Emma Parry</primarysponsorname>
    <primarysponsoraddress>Auckland District Health Board, Maternal-Fetal Medicine
Private Bag 92 024, Auckland Mail Centre. Auckland 1142</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Auckland Medical Research Foundation</fundingname>
      <fundingaddress>89 Grafton Road, Grafton. Auckland 1010</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Douglas Pharmacy</fundingname>
      <fundingaddress>PO Box 45027, Auckland 0651</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Lesley McCowan</sponsorname>
      <sponsoraddress>University of Auckland, Department of Obstetrics and Gynaecology
Private Bag 92 019, Auckland Mail Centre. Auckland 1142</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>We aimed to determine whether maintenance nifedipine treatment in women in spontaneous preterm labour and with positive fetal fibronectin would prolong pregnancy and reduce neonatal unit admission. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Auckland regional Ethics committee</ethicname>
      <ethicaddress>Research Integrity Unit
Level 10, Building 620
49 Symonds Street, Grafton, Auckland, 1010</ethicaddress>
      <ethicapprovaldate>5/02/2003</ethicapprovaldate>
      <hrec>AKY/02/00/148</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Emma Parry</name>
      <address>Auckland District Health Board, Maternal-Fetal Medicine, Private Bag 92 024, Auckland Mail Centre. Auckland. 1142.</address>
      <phone>+6493074992</phone>
      <fax />
      <email>EmmaP@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Carolien Roos</name>
      <address>Hospital Gelderse Vallei
Willy Brandtlaan 10
6716 RP Ede</address>
      <phone>+31611195142</phone>
      <fax />
      <email>carolienroos@hotmail.com</email>
      <country>Netherlands</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Carolien Roos</name>
      <address>Hospital Gelderse Vallei
Willy Brandtlaan 10
6716 RP Ede</address>
      <phone>+31611195142</phone>
      <fax />
      <email>carolienroos@hotmail.com</email>
      <country>Netherlands</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>